vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Primoris Services Corp (PRIM). Click either name above to swap in a different company.
Primoris Services Corp is the larger business by last-quarter revenue ($1.9B vs $1.1B, roughly 1.6× Elanco Animal Health Inc). Primoris Services Corp runs the higher net margin — 2.8% vs -24.1%, a 26.9% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 6.7%). Primoris Services Corp produced more free cash flow last quarter ($121.1M vs $46.0M). Over the past eight quarters, Primoris Services Corp's revenue compounded faster (14.7% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Primoris Services Corporation is a publicly traded specialty construction and infrastructure company based in the United States, with a particular focus on pipelines for natural gas, wastewater and water. As of 2014 it was a Fortune 1000 company.
ELAN vs PRIM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.9B |
| Net Profit | $-276.0M | $51.7M |
| Gross Margin | 51.5% | 9.4% |
| Operating Margin | -22.6% | 4.2% |
| Net Margin | -24.1% | 2.8% |
| Revenue YoY | 12.2% | 6.7% |
| Net Profit YoY | -3350.0% | -4.2% |
| EPS (diluted) | $-0.55 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $1.0B | $1.6B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.2B | $1.4B |
| Q4 25 | $-276.0M | $51.7M | ||
| Q3 25 | $-34.0M | $94.6M | ||
| Q2 25 | $11.0M | $84.3M | ||
| Q1 25 | $67.0M | $44.2M | ||
| Q4 24 | $-8.0M | $54.0M | ||
| Q3 24 | $364.0M | $58.4M | ||
| Q2 24 | $-50.0M | $49.5M | ||
| Q1 24 | $32.0M | $18.9M |
| Q4 25 | 51.5% | 9.4% | ||
| Q3 25 | 53.4% | 10.8% | ||
| Q2 25 | 57.5% | 12.3% | ||
| Q1 25 | 57.3% | 10.4% | ||
| Q4 24 | 50.9% | 10.6% | ||
| Q3 24 | 52.2% | 12.0% | ||
| Q2 24 | 58.2% | 11.9% | ||
| Q1 24 | 57.3% | 9.4% |
| Q4 25 | -22.6% | 4.2% | ||
| Q3 25 | -4.4% | 6.3% | ||
| Q2 25 | 2.0% | 6.7% | ||
| Q1 25 | 5.0% | 4.3% | ||
| Q4 24 | -5.0% | 5.0% | ||
| Q3 24 | 54.3% | 6.0% | ||
| Q2 24 | -2.7% | 5.5% | ||
| Q1 24 | 1.0% | 3.1% |
| Q4 25 | -24.1% | 2.8% | ||
| Q3 25 | -3.0% | 4.3% | ||
| Q2 25 | 0.9% | 4.5% | ||
| Q1 25 | 5.6% | 2.7% | ||
| Q4 24 | -0.8% | 3.1% | ||
| Q3 24 | 35.3% | 3.5% | ||
| Q2 24 | -4.2% | 3.2% | ||
| Q1 24 | 2.7% | 1.3% |
| Q4 25 | $-0.55 | $0.94 | ||
| Q3 25 | $-0.07 | $1.73 | ||
| Q2 25 | $0.02 | $1.54 | ||
| Q1 25 | $0.13 | $0.81 | ||
| Q4 24 | $-0.01 | $0.98 | ||
| Q3 24 | $0.73 | $1.07 | ||
| Q2 24 | $-0.10 | $0.91 | ||
| Q1 24 | $0.06 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $535.5M |
| Total DebtLower is stronger | $3.9B | $469.9M |
| Stockholders' EquityBook value | $6.5B | $1.7B |
| Total Assets | $13.4B | $4.4B |
| Debt / EquityLower = less leverage | 0.60× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $535.5M | ||
| Q3 25 | $505.0M | $431.4M | ||
| Q2 25 | $539.0M | $390.3M | ||
| Q1 25 | $487.0M | $351.6M | ||
| Q4 24 | $468.0M | $455.8M | ||
| Q3 24 | $490.0M | $352.7M | ||
| Q2 24 | $416.0M | $207.4M | ||
| Q1 24 | $345.0M | $177.6M |
| Q4 25 | $3.9B | $469.9M | ||
| Q3 25 | $4.0B | $486.0M | ||
| Q2 25 | $4.1B | $603.1M | ||
| Q1 25 | $4.4B | $612.0M | ||
| Q4 24 | $4.3B | $734.8M | ||
| Q3 24 | $4.4B | $903.7M | ||
| Q2 24 | $5.7B | $933.0M | ||
| Q1 24 | $5.8B | $951.7M |
| Q4 25 | $6.5B | $1.7B | ||
| Q3 25 | $6.7B | $1.6B | ||
| Q2 25 | $6.8B | $1.5B | ||
| Q1 25 | $6.4B | $1.4B | ||
| Q4 24 | $6.1B | $1.4B | ||
| Q3 24 | $6.5B | $1.4B | ||
| Q2 24 | $5.9B | $1.3B | ||
| Q1 24 | $6.1B | $1.2B |
| Q4 25 | $13.4B | $4.4B | ||
| Q3 25 | $13.6B | $4.6B | ||
| Q2 25 | $13.7B | $4.5B | ||
| Q1 25 | $12.9B | $4.2B | ||
| Q4 24 | $12.6B | $4.2B | ||
| Q3 24 | $13.3B | $4.2B | ||
| Q2 24 | $13.8B | $4.0B | ||
| Q1 24 | $14.0B | $4.0B |
| Q4 25 | 0.60× | 0.28× | ||
| Q3 25 | 0.59× | 0.30× | ||
| Q2 25 | 0.61× | 0.39× | ||
| Q1 25 | 0.69× | 0.42× | ||
| Q4 24 | 0.70× | 0.52× | ||
| Q3 24 | 0.67× | 0.67× | ||
| Q2 24 | 0.96× | 0.72× | ||
| Q1 24 | 0.95× | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $142.9M |
| Free Cash FlowOCF − Capex | $46.0M | $121.1M |
| FCF MarginFCF / Revenue | 4.0% | 6.5% |
| Capex IntensityCapex / Revenue | 5.4% | 1.2% |
| Cash ConversionOCF / Net Profit | — | 2.76× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $340.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $142.9M | ||
| Q3 25 | $219.0M | $182.9M | ||
| Q2 25 | $237.0M | $78.5M | ||
| Q1 25 | $-4.0M | $66.2M | ||
| Q4 24 | $177.0M | $298.3M | ||
| Q3 24 | $162.0M | $222.5M | ||
| Q2 24 | $200.0M | $16.1M | ||
| Q1 24 | $2.0M | $-28.5M |
| Q4 25 | $46.0M | $121.1M | ||
| Q3 25 | $127.0M | $148.4M | ||
| Q2 25 | $180.0M | $45.3M | ||
| Q1 25 | $-69.0M | $25.6M | ||
| Q4 24 | $130.0M | $270.0M | ||
| Q3 24 | $120.0M | $158.8M | ||
| Q2 24 | $166.0M | $-8.1M | ||
| Q1 24 | $-22.0M | $-38.9M |
| Q4 25 | 4.0% | 6.5% | ||
| Q3 25 | 11.2% | 6.8% | ||
| Q2 25 | 14.5% | 2.4% | ||
| Q1 25 | -5.8% | 1.6% | ||
| Q4 24 | 12.7% | 15.5% | ||
| Q3 24 | 11.7% | 9.6% | ||
| Q2 24 | 14.0% | -0.5% | ||
| Q1 24 | -1.8% | -2.8% |
| Q4 25 | 5.4% | 1.2% | ||
| Q3 25 | 8.1% | 1.6% | ||
| Q2 25 | 4.6% | 1.8% | ||
| Q1 25 | 5.4% | 2.5% | ||
| Q4 24 | 4.6% | 1.6% | ||
| Q3 24 | 4.1% | 3.9% | ||
| Q2 24 | 2.9% | 1.5% | ||
| Q1 24 | 2.0% | 0.7% |
| Q4 25 | — | 2.76× | ||
| Q3 25 | — | 1.93× | ||
| Q2 25 | 21.55× | 0.93× | ||
| Q1 25 | -0.06× | 1.50× | ||
| Q4 24 | — | 5.53× | ||
| Q3 24 | 0.45× | 3.81× | ||
| Q2 24 | — | 0.32× | ||
| Q1 24 | 0.06× | -1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
